Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05687136 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05687136 · ClinicalTrials.gov record · last posted 2026-08-24

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Name: Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors — clinical trial record (NCT05687136)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorNational Cancer Institute (NCI)

Started2024-06-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Protocol amendment history 2 changes detected by DataLookout

2026-08-22

Primary completion pushed: 2026-08-31 → 2027-08-31

2026-08-22

Completion pushed: 2026-08-31 → 2027-08-31

Trial Details

NCT Number	NCT05687136
Lead Sponsor	National Cancer Institute (NCI)
Conditions	Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Enrollment	66 participants
Start Date	2024-06-07
Primary Completion	2027-08-31 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-24